Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/31336 http://dx.doi.org/10.1111/j.1468-1293.2008.00665.x |
Resumo: | Short-term antiretroviral therapy (START) to prevent mother-to-child transmission (MTCT) is currently recommended for all HIV-1-infected pregnant women. the objective of this study was to assess the effect on CD4 cell counts and viral load dynamics the withdrawal of START after birth could generate.This was a 5-year cohort study involving HIV-1-infected pregnant women who presented with CD4 counts > 300 cells/mu L and had received START to prevent MTCT.Seventy-five pregnancies were assessed. in 24 cases, there was a history of antiretroviral therapy prior to prophylaxis. the median baseline CD4 count was 573 cells/mu L. in 75% of cases, prophylaxis was started after 26.6 weeks of gestation. the median CD4 cell count increase over baseline during prophylaxis was 24.5%. in only five cases did HIV-1 viral load remain detectable during prophylaxis. After START, CD4 cell counts did not drop significantly, and the HIV-1 viral load plateau was near the baseline level. the estimated mean time for CD4 count to fall below 300 cells/mu L was 3.5 years and was directly associated with high baseline CD4 cell count, as well as with CD4 increase after prophylaxis, whereas it was negatively correlated with previous use of antiretroviral (ARV) drugs and persistence of detectable HIV-1 viral load during prophylaxis.A potent, well-tolerated prophylactic ARV regimen can improve CD4 cell counts during and after START. in women receiving such prophylaxis, there is a remarkable time interval for CD4 cell counts to drop to levels that indicate treatment. |
id |
UFSP_3f2fc90f40d3062501ec2a70f5168b99 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/31336 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Palacios, Ricardo [UNIFESP]Senise, Jorge Figueiredo [UNIFESP]Vaz, Maria José Rodrigues [UNIFESP]Diaz, Ricardo Sobhie [UNIFESP]Castelo, Adauto [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2016-01-24T13:52:18Z2016-01-24T13:52:18Z2009-03-01Hiv Medicine. Malden: Wiley-Blackwell Publishing, Inc, v. 10, n. 3, p. 157-162, 2009.1464-2662http://repositorio.unifesp.br/handle/11600/31336http://dx.doi.org/10.1111/j.1468-1293.2008.00665.x10.1111/j.1468-1293.2008.00665.xWOS:000263601000004Short-term antiretroviral therapy (START) to prevent mother-to-child transmission (MTCT) is currently recommended for all HIV-1-infected pregnant women. the objective of this study was to assess the effect on CD4 cell counts and viral load dynamics the withdrawal of START after birth could generate.This was a 5-year cohort study involving HIV-1-infected pregnant women who presented with CD4 counts > 300 cells/mu L and had received START to prevent MTCT.Seventy-five pregnancies were assessed. in 24 cases, there was a history of antiretroviral therapy prior to prophylaxis. the median baseline CD4 count was 573 cells/mu L. in 75% of cases, prophylaxis was started after 26.6 weeks of gestation. the median CD4 cell count increase over baseline during prophylaxis was 24.5%. in only five cases did HIV-1 viral load remain detectable during prophylaxis. After START, CD4 cell counts did not drop significantly, and the HIV-1 viral load plateau was near the baseline level. the estimated mean time for CD4 count to fall below 300 cells/mu L was 3.5 years and was directly associated with high baseline CD4 cell count, as well as with CD4 increase after prophylaxis, whereas it was negatively correlated with previous use of antiretroviral (ARV) drugs and persistence of detectable HIV-1 viral load during prophylaxis.A potent, well-tolerated prophylactic ARV regimen can improve CD4 cell counts during and after START. in women receiving such prophylaxis, there is a remarkable time interval for CD4 cell counts to drop to levels that indicate treatment.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Universidade Federal de São Paulo, Hosp São Paulo, NUPAIG, Multidisciplinary Grp Infect Dis Pregnancy, BR-04039032 São Paulo, BrazilUniversidade Federal de São Paulo, Hosp São Paulo, NUPAIG, Multidisciplinary Grp Infect Dis Pregnancy, BR-04039032 São Paulo, BrazilCNPq: 139/96Web of Science157-162engWiley-BlackwellHiv Medicinehttp://olabout.wiley.com/WileyCDA/Section/id-406071.htmlinfo:eu-repo/semantics/openAccessantiretroviral agentsCD4 T-cell countHIV-1vertical transmissionShort-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothersinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlereponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/313362022-06-02 09:02:15.386metadata only accessoai:repositorio.unifesp.br:11600/31336Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:13:26.780095Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers |
title |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers |
spellingShingle |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers Palacios, Ricardo [UNIFESP] antiretroviral agents CD4 T-cell count HIV-1 vertical transmission |
title_short |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers |
title_full |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers |
title_fullStr |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers |
title_full_unstemmed |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers |
title_sort |
Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers |
author |
Palacios, Ricardo [UNIFESP] |
author_facet |
Palacios, Ricardo [UNIFESP] Senise, Jorge Figueiredo [UNIFESP] Vaz, Maria José Rodrigues [UNIFESP] Diaz, Ricardo Sobhie [UNIFESP] Castelo, Adauto [UNIFESP] |
author_role |
author |
author2 |
Senise, Jorge Figueiredo [UNIFESP] Vaz, Maria José Rodrigues [UNIFESP] Diaz, Ricardo Sobhie [UNIFESP] Castelo, Adauto [UNIFESP] |
author2_role |
author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Palacios, Ricardo [UNIFESP] Senise, Jorge Figueiredo [UNIFESP] Vaz, Maria José Rodrigues [UNIFESP] Diaz, Ricardo Sobhie [UNIFESP] Castelo, Adauto [UNIFESP] |
dc.subject.eng.fl_str_mv |
antiretroviral agents CD4 T-cell count HIV-1 vertical transmission |
topic |
antiretroviral agents CD4 T-cell count HIV-1 vertical transmission |
description |
Short-term antiretroviral therapy (START) to prevent mother-to-child transmission (MTCT) is currently recommended for all HIV-1-infected pregnant women. the objective of this study was to assess the effect on CD4 cell counts and viral load dynamics the withdrawal of START after birth could generate.This was a 5-year cohort study involving HIV-1-infected pregnant women who presented with CD4 counts > 300 cells/mu L and had received START to prevent MTCT.Seventy-five pregnancies were assessed. in 24 cases, there was a history of antiretroviral therapy prior to prophylaxis. the median baseline CD4 count was 573 cells/mu L. in 75% of cases, prophylaxis was started after 26.6 weeks of gestation. the median CD4 cell count increase over baseline during prophylaxis was 24.5%. in only five cases did HIV-1 viral load remain detectable during prophylaxis. After START, CD4 cell counts did not drop significantly, and the HIV-1 viral load plateau was near the baseline level. the estimated mean time for CD4 count to fall below 300 cells/mu L was 3.5 years and was directly associated with high baseline CD4 cell count, as well as with CD4 increase after prophylaxis, whereas it was negatively correlated with previous use of antiretroviral (ARV) drugs and persistence of detectable HIV-1 viral load during prophylaxis.A potent, well-tolerated prophylactic ARV regimen can improve CD4 cell counts during and after START. in women receiving such prophylaxis, there is a remarkable time interval for CD4 cell counts to drop to levels that indicate treatment. |
publishDate |
2009 |
dc.date.issued.fl_str_mv |
2009-03-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T13:52:18Z |
dc.date.available.fl_str_mv |
2016-01-24T13:52:18Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Hiv Medicine. Malden: Wiley-Blackwell Publishing, Inc, v. 10, n. 3, p. 157-162, 2009. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/31336 http://dx.doi.org/10.1111/j.1468-1293.2008.00665.x |
dc.identifier.issn.none.fl_str_mv |
1464-2662 |
dc.identifier.doi.none.fl_str_mv |
10.1111/j.1468-1293.2008.00665.x |
dc.identifier.wos.none.fl_str_mv |
WOS:000263601000004 |
identifier_str_mv |
Hiv Medicine. Malden: Wiley-Blackwell Publishing, Inc, v. 10, n. 3, p. 157-162, 2009. 1464-2662 10.1111/j.1468-1293.2008.00665.x WOS:000263601000004 |
url |
http://repositorio.unifesp.br/handle/11600/31336 http://dx.doi.org/10.1111/j.1468-1293.2008.00665.x |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Hiv Medicine |
dc.rights.driver.fl_str_mv |
http://olabout.wiley.com/WileyCDA/Section/id-406071.html info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://olabout.wiley.com/WileyCDA/Section/id-406071.html |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
157-162 |
dc.publisher.none.fl_str_mv |
Wiley-Blackwell |
publisher.none.fl_str_mv |
Wiley-Blackwell |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460264308375552 |